Spring 2024 Provincial Colposcopy Community of Practice (CoP)

Webinar 2 May 24



Land acknowledgement




Agenda

ltem	Presenter	Time
Welcome and introductions	Riley Crotta	7:30 – 7:35 am
Ontario Cervical Screening Program (OCSP) updates	Dr. Dustin Costescu	7:35 – 7:40 am
HPV testing implementation update	Dr. Dustin Costescu	7:40 – 7:45 am
Trends in cervical screening and colposcopy in Ontario	Dr. Rachel Kupets	7:45 – 7:50 am
Case study #1: Management of adenocarcinoma in situ (AIS) histology with negative margins	Dr. Dustin Costescu	7:50 – 8:15 am
Colposcopy quality reports	Dr. Rachel Kupets	8:15 – 8:25 am
Questions from the field	Dr. Dustin Costescu	8:25 – 8:40 am
Case study #2: Management of adenocarcinoma in situ (AIS) histology with positive margins	Dr. Rachel Kupets	8:40 – 8:55 am
Concluding remarks	Dr. Dustin Costescu	8:55 – 9:00 am

Housekeeping items


- Please mute yourself when you are not speaking
- Please turn on your webcam during discussions
- Please use the chat box or raise hand option to ask questions or share comments




Poll options

- Polls will either pop up on your screen, appear in the chat box, or both
- You can respond in either location

Poll pop-up



Poll in chat box



Accreditation

Royal College of Physicians and Surgeons of Canada – Section 1:

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, approved by Continuing Professional Development, Faculty of Medicine, University of Toronto. You may claim up to a maximum of 1.5 hours (credits are automatically calculated).

To receive a letter of accreditation for 1.5 credit hours, you must participate in today's event

Thank you to our CoP Planning Committee

Dr. Robert Di Cecco

Dr. Hélène Gagne

Dr. Nadia Ismiil

Dr. Felice Lackman

Recording of CoP spring webinar is underway

Please note that this session will be recorded and will be available on the Colposcopy CoP Resources Hub in the coming weeks. You can access the hub here:

cancercareontario.ca/ColposcopyHub

Learning objectives

- Following this webinar, participants will better understand:
 - What to expect leading up to the launch of HPV testing implementation
 - Trends in cervical screening and colposcopy services in Ontario
 - How to access the physician-level cervical screening and colposcopy quality reports
 - Management of adenocarcinoma in situ (AIS) histology according to margin status

OCSP updates

7:35 - 7:40am

Dr. Dustin Costescu

Regional Cervical Screening and Colposcopy Leads

Regional Cancer Program	Lead
Erie St. Clair	Dr. Rahi Victory
South West	Dr. Robert DiCecco
Waterloo Wellington	Dr. Cheryl Lee
Hamilton Niagara Haldimand Brant	Dr. Andra Nica
Central West/ Mississauga Halton	Dr. Tiffany Zigras
Toronto Central	Dr. Michael Shier
Central	Dr. Felice Lackman
Central East	Dr. Nathan Roth
South East	Dr. Elena Park
Champlain	Dr. Hélène Gagné
North Simcoe Muskoka	Dr. Jennifer Tomas
North East	Dr. Karen Splinter
North West	Dr. Naana Jumah

Colposcopy resources

- The OCSP has the following resources to help support colposcopists and other providers in the colposcopy community:
 - Guideline-based clinical tools
 - Sample declined referral and discharge letter templates
 - Slides and recordings from past CoP webinars

Resources are available on our Colposcopy
CoP Resources Hub:
cancercareontario.ca/colposcopyhub

Update: HPV testing implementation

7:40 - 7:45am

Dr. Dustin Costescu

HPV testing implementation vendor partners



When to expect communications and resources to support your change management efforts



Self-collected HPV testing

- There is evidence that self-collected HPV testing can improve screening participation, particularly for under/never screened populations
- There are important regulatory, clinical and implementation considerations that must be considered and addressed before integrating self-collected HPV testing into the OCSP
- A phased approach to implementation in Ontario will allow us to determine how best to integrate self-collected HPV testing into the OCSP

Timeline of Colposcopy CoP webinars


Topics: Colposcopy pathways part October 2024 January 2025 **November 2024 Topics: Cervical** Topics: screening & Colposcopy vaginal vault pathways part testing Launch date: Spring 2025

Trends in cervical screening and colposcopy in Ontario

7:45 – 7:50am

Dr. Rachel Kupets


Cervical cancer incidence rate



Year of diagnosis


Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2023. Toronto, ON: Canadian Cancer Society; 2023.

Total number of cervical pre-cancers and invasive cancers




N = total cases per year


OCSP participation (ages 21 – 69)




Age is driving decline in participation



OCSP participation by material deprivation



High-grade cytology test with no follow-up in 6 months



Colposcopists and primary care providers should continue to collaborate to ensure that people with high-grade cytology results have a follow-up colposcopy

Case study #1: Management of AIS histology with negative margins

7:50 - 8:15am

Dr. Dustin Costescu

AIS on the cervix




Image provided by Dr. Michael Shier

Patient history


- Age 30
- Referred to colposcopy with atypical glandular cells-favor neoplastic (AGC-N) cytology
- At initial colposcopy visit:
 - An area of abnormality is detected
 - A biopsy is performed
 - Intrauterine device (IUD) strings are noted
- AIS histology is confirmed

Answer poll in chat or via pop-up

What is your next step?

- A. Perform a loop electrosurgical excision procedure (LEEP)
- B. Perform a cold knife cone
- C. Perform a cytology test
- D. A or B

Treatment and management of AGC/AIS



LEEP vs. cold knife cone

The evidence shows that both LEEP and cold knife cone are effective treatments for AIS

		95% confidence interval	P-value
338	0.8	0.3-2.0	0.578

Reference: Munro A, Leung Y, Spilsbury K, Stewart CJ, Semmens J, Codde J, et al. Comparison of cold knife cone biopsy and loop electrosurgical excision procedure in the management of cervical adenocarcinoma in situ: What is the gold standard? Gynecol Oncol 2015 May;137(2):258-63

Colposcopy visit #2

 At the second colposcopy visit, you perform a LEEP followed by an endocervical curettage (ECC)

How would you perform a LEEP/ECC while managing patient's IUD strings?

A. Carefully perform LEEP/ECC while trying to avoid IUD strings

Answer poll in chat or via pop-up

- B. Push the IUD strings into the cervix and perform LEEP/ECC
- C. Remove IUD, perform LEEP/ECC and replace IUD immediately
- D. Remove IUD, perform LEEP/ECC and replace IUD at follow-up visit

Discussion

Type in chat box



How do you manage a patient's IUD while performing a LEEP/ECC?

Colposcopy visit #2 results


- AIS histology is detected on the LEEP specimen, ECC is normal and margins are negative
- Future fertility is desired

Answer poll in chat or via pop-up

What is your next step?

- A. Follow-up in colposcopy in 3 months
- B. Follow-up in colposcopy in 6 months
- C. Follow-up in colposcopy in 12 months
- D. Refer for expert opinion

Treatment and management of AGC/AIS



Post-treatment colposcopy visit


- At the post-treatment colposcopy visit in 6 months, AIS is not detected and a cytology test and an ECC are carried out
- ECC is normal and cytology test result is normal

How many more colposcopy visits over how many years are required if histology ≤ LSIL (low-grade squamous intraepithelial lesion), and all cytology results are normal at subsequent visits?


- A. 4 visits over 2 years
- B. 3 visits over 3 years
- C. 8 visits over 5 years
- D. Until hysterectomy is performed

Answer poll in chat or via pop-up

Post-treatment management for AIS



Risk of recurrence and progression to cervical cancer



	Rate of cervical cancer detected within 5 years of treatment
HSIL*	0.20%
AIS	0.39%

^{*}defined in study as CIN3

Key take-aways:

- People treated for AIS histology have an increased risk of recurrence and progression to cervical cancer compared to people treated for HSIL histology
- Longer follow-up in colposcopy is recommended for people treated for AIS histology

Colposcopy quality reports


8:15 - 8:25am

Dr. Rachel Kupets

2023 Quality Report Accomplishments

- 439 individual physician reports were made accessible to colposcopists on September 18
- 115 facility reports (F/R/P) sent to facility contacts and their respective Cervical Screening and Colposcopy Leads and Regional Directors (RDs) on September 26
- 14 regional reports and regional summaries were sent to the respective Regional Vice Presidents, RDs and RBILs on September 20

Sample: 2023 physician report



How many colposcopists saw their report?

• In mid-September 2023, physician-level reports were made accessible to 439 colposcopists.

	Colposcopist Volume 2023
Colposcopists with a report	439
ONE ID account holders	277 (63%)
eReport access	124 (28%)


If you don't have a ONE ID account

Step 1:

Physicians can self-register for ONE ID via the CPSO website using your account credentials.

Step 2:


Once signed up, a ONE ID username (first.last@oneid.on.ca) and password will be generated (ONE ID credentials). Be sure to note this information in a secure location.



1	2	
Register for a ONE ID account	Enroll for Digital Health Services	
Duick setup! Register in minutes using pre-populated.	ConnectingOntario Clinical Viewers is a secure,	
nformation from CPSO.	web-based portal for health care organizations that	
	providesreal-time access to comprehensive	
To begin the sign up process, reviewe and agree to the Consent Statement below, then click 'Sign Up for ONE ID'.	digital health records. Learn more about ConnectingOntario	
	ClinicalConnect Regional Clinical Viewer is a secure,	
ou will be directed to the ONE ID website to complete your	web-based portal that gives real-time access to	
egistration.	patients' electronic medical information for healtcare providers	
	in South West Onatrio.	
Weed Help? Refer to the <u>Registration Guide</u> and read our <u>EADs</u> . If you have questions about ONE ID,	Learn more about <u>ClinicalConnect</u> .	
contact Ontario Health's Registration Agent ONEIDRegistrationAgents/bontariohealth.ca	Ontario Health's Ontario Telemedicine Network	
	(OTN) Hub is a private and secure community	
	for practicing telemedicine, connecting with peers and	
	specialists and online learning. Learn more about OTNhub.	
	Ontario Health's Cancer Care Onatrio (CCO) online portal	
	provides secure access to screening	
	activity reprots for primary care physicians	
	and clinician-level quality reports (e.g., for colonoscopy and	
	mammography). Learn more about CCO.	
Regi	ster Now	
CONTROL COMPANY AND ENGINEERING TO THE TREET OF THE CONTROL OF THE		
and registration class for the purposes listed above. I further conse	and the Particular Mandala and Continue and Amilian	

Access your report via eReport portal

- Navigate to eReport portal: <u>https://ereport.ontariohealth.ca</u>
- 2. Select ONE ID and login using your ONE ID account credentials





Reminder: Use your quality report to fulfill CPSO requirements

Quality Improvement Program


- It is mandatory to participate in one of these programs every
 5 years unless physician is retiring in the next 3-6 months
- This requirement is irrespective of clinical specialty
- Either of these streams can earn physicians Continued Professional Development (CPD) credits

Quality Improvement for Hospitals

Quality Improvement for Individuals

Quality Improvement for Individuals

- Data-Driven Quality Improvement is designed to get physicians looking at their own practice-level data to reflect on how they deliver health care to their patients and to identify opportunities for improvement.
- The physician report can fulfill the QI program either as a colposcopy practice or an individual physician.



2024 Quality Reports

May 2024: Colposcopy Quality Facility Survey

- The survey will assess facilities' adherence to the quality standards.
- Responses to the survey will be reported in the 2024 cervical screening and colposcopy quality reports.

September 2024: Report Dissemination

 The 2024 cervical screening and colposcopy quality provincial, regional, facility and physician reports will be released in mid-September.

Questions from the field

8:25 – 8:40am

Dr. Dustin Costescu

Question from the field

Question:

What is the best approach to colposcopy in pregnancy?

Answer:

- Aim of colposcopy in pregnancy is to exclude invasive disease
- A biopsy can be performed when there is suspicion of invasive disease
- If possible, defer treatment until pregnancy has concluded
- For more information, refer to the 2023 Canadian Colposcopy Guideline: A Risk-Based Approach to Management and Surveillance of Cervical Dysplasia

Question from the field

Question:

What is the screening cessation age for patients not treated in colposcopy?

Answer:

- If someone is referred to colposcopy after age 70 and no lesion is detected, they can stop screening upon discharge from colposcopy
- In some cases, recommendations for screening cessation can be made at a colposcopist's discretion based on individualized risk factors

Case study #2: Management of AIS histology with positive margins

8:40 - 8:55am

Dr. Rachel Kupets

Patient history / colposcopy visits

- Age 30
- Referred with atypical glandular cells, not otherwise specified (AGC-NOS) cytology
- At initial colposcopy visit, histology = AIS
- At second colposcopy visit, a LEEP is performed followed by an ECC. ECC is normal and margins
 are positive

What is your next step?

Answer poll in chat or via pop-up

- A. Repeat LEEP
- B. Repeat colposcopy in 6 months
- C. A or B
- D. Perform a cytology test

Positive margins are a risk factor for AIS recurrence and persistence

TABLE 2. Loop Electrosurgical Excision Procedure/Cone Biopsy Margin Status and Follow-up Results (Including 8 Pap Only)

	AIS or adenocarcinoma, n (%)	Negative, n (%)	Total, n (%)	к
Margin positive	25 (47.2)	28 (52.8)	53 (32.7)	
Margin negative	$10 (9.3)^a$	97 (90.7)	107 (67.3)	
Total	35 (21.9)	125 (78.1)	160 (100.0)	0.45
$^{a}p < .001.$				

Key take-aways:

- AIS persistence/recurrence rate was significantly higher for those with positive margins compared to those with negative margins
- People with AIS histology and positive margins should continue with close monitoring or treatment in colposcopy until negative margins are achieved

HPV status

- HPV status is also associated with AIS recurrence and progression to cervical cancer
- A study showed that a positive HPV test result was an independent predictor of AIS recurrence and was most strongly associated with progression to cervical cancer
 - AIS recurrence (OR = 2.72; 95% CI: 1.08 6.87; p = 0.033)
 - Progression to cervical cancer (OR = 3.74; 95% CI: 1.84 7.61; p = 0.0001)

OR: Odds ratio

CI: Confidence interval

Key take-away

HPV tests can provide important data to inform risk-based management of people treated for AIS histology in colposcopy and will be used in future state pathways

Colposcopy visit #3

- A repeat LEEP shows AIS with negative margins
- Future fertility is desired
- Colposcopy is repeated in 6 months

Colposcopy visit #4


- A colposcopy repeated in 6 months shows:
 - AIS cytology
 - Positive ECC

Answer poll in chat or via pop-up

What is your next step?

- A. Discuss a hysterectomy
- **B.** Repeat LEEP
- C. Discharge to primary care

Treatment and management of AGC/AIS



Discussion

Type in chat box



What factors would you consider in recommending a hysterectomy for patients with AIS histology?

Hysterectomy for people treated for AIS histology

- Hysterectomy can be considered when childbearing is complete in the following circumstances:
 - Negative margins cannot be achieved despite adequate diagnostic excisional procedure (DEP)
 excision
 - Cervix cannot be assessed adequately (e.g., post-treatment stenosis)
 - People who are persistently positive for HPV (people who have consecutive negative HPV results after treatment for AIS are unlikely to benefit from hysterectomy)
 - People who are not able to follow post-treatment recommendations, in particular those with residual risk of AIS

Final remarks

8:55 – 9:00am

Dr. Dustin Costescu

What's next?

- Please fill out the post-webinar survey survey link will be emailed to CoP webinar attendees
- Share your feedback and questions with us at <u>ColposcopyCoP@ontariohealth.ca</u>

Next CoP webinar: October 2024 (dates TBD)

We will begin to review future state recommendations



Thank you!